Postpartum plasma PGF metabolite profile in cows with dystocia and/or retained placenta, and effect of fenprostalene on uterine involution and reproductive performance.
Objectives of this study were to show postpartum plasma PGF2 alpha metabolite (PGFM) profile, to clarify whether endogenous PGF2 alpha plays a certain role in the uterine involution in cows with dystocia and/or retained placenta, and to examine the effects of fenprostalene, a long-acting PGF2 alpha analog, on the uterine involution and reproductive performance of the cows with abnormal puerperium. A group of 27 cows with dystocia and/or retained placenta showed a massive release of PGF2 alpha after parturition as indicated by a rise of plasma concentrations of PGFM, significantly higher than 33 cows with normal puerperium. The duration of the elevated plasma PGFM concentrations in the cows with abnormal puerperium was shorter than that of the normal cows. In cows with normal puerperium, those showing relatively longer duration of elevated plasma PGFM levels needed a shorter period for postpartum uterine involution than the cows showing a shorter duration of the PGFM elevation (P < 0.01), while no such relationship was observed in cows with abnormal puerperium. In field trials, an administration of an exogenous PGF2 alpha, fenprostalene, at 7 to 10 days (78 cows) or 14 to 28 days postpartum (74 cows) was found to be effective in facilitating uterine involution and resumption of ovarian cyclicity, and improved reproductive performance. It may be concluded that a large amount of PGF2 alpha is released for a relatively shorter period in cows after dystocia and/or retained placenta and the elevation of PGFM is not responsible for the uterine involution. The administration of the exogenous PGF2 alpha was shown to be effective at improving the postpartum reproductive performance of cows with abnormal puerperium.
Nakao
T
T
Department of Veterinary Obstetrics and Gynecology, School of Veterinary Medicine, Rakuno Gakuen University, Hokkaido, Japan.
Gamal
A
A
Osawa
T
T
Nakada
K
K
Moriyoshi
M
M
Kawata
K
K
D000020:Abortifacient Agents, Nonsteroidal / Q000494:pharmacology*; D000818:Animals; D002417:Cattle; D002418:Cattle Diseases / Q000097:blood* / Q000503:physiopathology; D015237:Dinoprost / Q000097:blood* / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004420:Dystocia / Q000097:blood / Q000503:physiopathology / Q000662:veterinary*; D004716:Endometritis / Q000503:physiopathology / Q000662:veterinary; D005260:Female; D018457:Placenta, Retained / Q000097:blood / Q000503:physiopathology / Q000662:veterinary*; D049590:Postpartum Period / Q000097:blood* / Q000502:physiology; D011247:Pregnancy; D011461:Prostaglandins F, Synthetic / Q000494:pharmacology*; D011897:Random Allocation; D012098:Reproduction / Q000187:drug effects* / Q000502:physiology; D013997:Time Factors; D014599:Uterus / Q000033:anatomy & histology / Q000187:drug effects* / Q000502:physiology
D000020:Abortifacient Agents, Nonsteroidal; D011461:Prostaglandins F, Synthetic; D015237:Dinoprost; C039153:fenprostalene